Shire’s Mesavance User Fee Date Extended To Jan. 21
This article was originally published in The Pink Sheet Daily
Executive Summary
Delay allows FDA to review supplemental Phase I dose absorption study for ulcerative colitis treatment.
You may also be interested in...
Shire's Lialda Launch For Ulcerative Colitis Will Focus On Dosing Convenience
Shire is planning an sNDA for a remission maintenance claim within two years, the firm tells "The Pink Sheet" DAILY.
Shire's Lialda Launch For Ulcerative Colitis Will Focus On Dosing Convenience
Shire is planning an sNDA for a remission maintenance claim within two years, the firm tells "The Pink Sheet" DAILY.
Salix Gets FDA Approval For Colazal in Pediatric UC Patients
Colazal becomes first 5-ASA approved for pediatric ulcerative colitis, firm says.